IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients

Table 2 Univariate and multivariate analysis of baseline factors associated with hepatitis C virus RNA reduction < 1 log₁₀ IU/mL at week 4 on treatment n (%)

Baseline factors	Univariate			Multivariate
	HCV RNA drop <1 log10: w4	HCV RNA drop≥log10: w4	P value	OR	95%CI	P value
	(n = 26)	(n = 92)
Age, yr	49 (14)	49 (18)	NS	-	-	NS
Male gender	15 (26)	47 (74)	NS	-	-	NS
BMI, kg/m2	23 (2)	24 (4)	NS	-	-	-
AST, IU/mL	90 (46)	67 (74)	0.032	1.01	0.99-1.02	NS
ALT, IU/mL	73 (60)	49 (44)	0.002	0.97	0.95-0.99	0.018
gGT, IU/mL	68 (71)	39 (43)	0.001	0.99	0.98-0.99	0.009
Platelets, 109 L	151 (93)	196 (83)	0.019	-	-	NS
APRI index	0.6 (1.2)	0.4 (0.6)	0.033	-	-	NS
Basal HCV RNA, log IU/mL	6.1 (0.8)	6 (1.1)	NS	-	-	-
Fibrosis F3/F4	11 (58)	48 (80)	NS	-	-	NS
IL28B rs8099917_TG/GG	21 (81)	38 (41)	< 0.001	7.90	1.99-31.18	0.003
IL28B rs12979860_CT/TT	23 (88)	65 (71)	NS	-	-	NS

Data are reported as median (interquartile range) and frequencies (%). IL: Interleukin; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; gGT: Gamma-glutamyl transpeptidase; Null-R: Null-responders; NS: Not significant.